...Continued

Bright Data Survey Reveals Retail, Banking and Travel Organizations are Turning to Acquisitions and External Partners to Support Increase in Web Data Collection Efforts

Retrieved on: 
Tuesday, October 25, 2022
Retail, Other Professional Services, Data Management, Other Communications, Technology, Finance, Other Travel, Communications, Other Consumer, Professional Services, Travel, Other Retail, Software, Digital Marketing, Consumer, Time, Organization, Research, Master class, Founder CEO, Multimedia, ...Continued, Research Executive Agency, Canada, Technology, Data management, You, Budget, Acquisition, CEO, Infographic, Red Point Provincial Park, CEST, Travel, Â, Online shopping, Cryptocurrency

New research from Bright Data , the industry-leading web data platform, and independent research firm Vanson Bourne reveals how pervasive and crucial web data is to business strategies across the retail, travel and banking sectors.

Key Points: 
  • New research from Bright Data , the industry-leading web data platform, and independent research firm Vanson Bourne reveals how pervasive and crucial web data is to business strategies across the retail, travel and banking sectors.
  • Amid growing market demand for insights gleaned from web data, the research also suggests that organizations are searching to make acquisitions or find external partners to support their web data efforts.
  • Ninety-seven percent of those surveyed consider it important to gain access to multiple web data sources or data sets; this includes specifically tailored data sets.
  • It is clear that in the past two years the market reliance on web data has significantly increased," said Or Lenchner, CEO at Bright Data.

Notice of Failure to Satisfy a Continued Listing Rule

Retrieved on: 
Friday, September 23, 2022
Transfer, Company, Compliance, Private Securities Litigation Reform Act, Calendar, U.S. Securities and Exchange Commission, Happiness, Student, Nasdaq, The Company, Security (finance), ...Continued, Risk management, Notice

LISHUI, China, Sept. 23, 2022 /PRNewswire/ -- On September 15, 2022, Lixiang Education Holding Co., Ltd (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Global Market ("Nasdaq") indicating that the Company was not in compliance with Listing Rule 5450(a)(2) (the "Minimum Public Holders Rule"), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market.

Key Points: 
  • Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
  • LISHUI, China, Sept. 23, 2022 /PRNewswire/ --On September 15, 2022, Lixiang Education Holding Co., Ltd (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Global Market ("Nasdaq") indicating that the Company was not in compliance with Listing Rule 5450(a)(2) (the "Minimum Public Holders Rule"), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market.
  • The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market.
  • If Nasdaq acceptsCompany's plan, Nasdaq may grantthe Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with the Minimum Public Holders Rule.

Montrose Environmental Group Publishes Second Annual ESG Report

Retrieved on: 
Wednesday, September 7, 2022
Sustainability, Environmental Health, Environment, Security (finance), COVID-19, Safety, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Soil, Engineering, ...Continued, Achievement, Solution, Biophysical environment, DF, Board, Political movement, Atmosphere, U.S. Securities and Exchange Commission, Diversity, Goal, Social responsibility, Water, Company, MEG, ESG, PFAS, Forward-looking statement, GHG, Renewable energy, Risk management

Montrose Environmental Group, Inc. (Montrose) (NYSE:MEG) today released its second Environmental, Social, and Governance (ESG) Report.

Key Points: 
  • Montrose Environmental Group, Inc. (Montrose) (NYSE:MEG) today released its second Environmental, Social, and Governance (ESG) Report.
  • The 2022 ESG report highlights Montroses priorities, initiatives, and continued dedication to environmental stewardship, social responsibility, and ethical and secure business practices.
  • With this second report, we are publicly articulating our ESG goals to drive further action with a focus on purpose and transparency and to further create shareholder value.
  • To learn more about Montroses contributions toward a better, more sustainable and equitable future, please read its comprehensive 2022 ESG Report here .

SF Intra-City Interim Revenue Reached RMB4.48 billion, with 28% Growth in Revenue from External Customers

Retrieved on: 
Tuesday, August 30, 2022
Master service agreement, Yoy, Technology, Trust, City, ...Continued, Solution, Pressure, Holiday, Income, Company, Mercer (consulting firm), Group, The Group, SF, Face, Ecosystem, CLS, Growth, Efficiency, Film, Fine chemical, Video game, Retail, Online shopping, Food delivery

The interim results showed steady revenue growth, further increases in gross profit and gross margin, and continued improvement in core business indicators, resulting in a solid performance.

Key Points: 
  • The interim results showed steady revenue growth, further increases in gross profit and gross margin, and continued improvement in core business indicators, resulting in a solid performance.
  • SF Intra-City said, "Following our successful full year performance, we are pleased that the Company continued to achieve encouraging interim results this year.
  • In particular, non-food delivery scenarios posted strong performance, with revenue increasing by 32.4% YoY to RMB1,051.2 million.
  • SF Intra-City also strategically cooperated with SF Holding Group's ecosystem participants to create integrated solutions for customers, namely "front-end warehousing + mid-end trunk + intra-city on-demand delivery".

Diabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO

Retrieved on: 
Tuesday, August 23, 2022
Medical Supplies, Medical Devices, Health, Diabetes, General Health, Biotechnology, Partnership, BD (company), CEO, Technology, Safety, National Health Service, ...Continued, Type 1 diabetes, National Health Service (England), Physician, Lancet, Multimedia, American Medical Group Association, Type 2 diabetes, Patient, Insulin, Leadership, FDA, Therapy, Risk, Health, Medical device, Pharmaceutical industry, Hygieia

Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.

Key Points: 
  • Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.
  • Lawrence is an experienced CEO who previously led three companies including CeQur, a company that makes insulin patch pumps to treat type 2 diabetes.
  • Previously, he led the diabetes business at Becton Dickinson (now Embecta), the worlds leading manufacturer of insulin syringes and pen needles.
  • Now, with Doug serving as CEO, we will work together to build the nations leading network of diabetes clinics.

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 16, 2022
Biotechnology, Genetics, Health, Clinical Trials, U.S. Securities and Exchange Commission, Risk, CEO, Security (finance), Research, Patient, Collaboration, Protocol, MD, ...Continued, Organ dysfunction, Disease, Family, Industry, Diagnosis, Neuron, Technology, Lysosome, Congress, Safety, Doctor of Philosophy, Company, Science, Internet, Nasdaq, Conference, Death, WITS, Standard of care, Priority review, Niemann–Pick disease, Therapy, Cell, Cholesterol, Senior advisor, Form 10-K, EMA, CYTH, Organization, Trial of the century, Association, Oxidative stress, Expanded access, GSC, Genetic disorder, NPC1, IND, University of the Witwatersrand, PIP, NPC, SOC, Global, University, Adult, Pharmaceutical industry, Medical device, EU

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2022 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2022 and provided a business update.
  • Our primary focus remains on advancing our clinical programs evaluating Trappsol Cyclo for the treatment of NPC and Alzheimers disease.
  • Additionally, Cyclo Therapeutics received a positive opinion from the Paediatric Committee (PDCO) of the EMA and agreement on its Paediatric Investigation Plan (PIP) for Trappsol Cyclo.
  • Cyclo Therapeutics is also planning to evaluate Trappsol Cyclo for the treatment of Alzheimers Disease, targeting the reduction of amyloid beta and tau.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, August 11, 2022
Serum, PROC, Risk, ASCO, Metastasis, GLOBE, ORR, SEC, Clinical trial, Research, Annual report, Patient, Paclitaxel, Nivolumab, DABT, KOL, US, PFS, Toxic epidermal necrolysis, ...Continued, Terminology, Addition, Industry, Private Securities Litigation Reform Act, GAS6, BLA, Ovarian cancer, CMC, European Commission, Tectonic evolution of the Aravalli Mountains, Forward-looking statement, COVID-19, ITT, Kidney, Royal commission, Cancer, FDA, Population, Pancreas, Review, Company, Pancreatic cancer, Therapy, Lists of people executed in the United States, AXL, Progression-free survival, Pharmaceutical industry, Online gambling, Platinum, Cancer (disambiguation)

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
  • We continued to achieve great progress for Aravive in the second quarter of 2022.
  • Our Phase 1b trial in pancreatic cancer has completed enrollment and updated results are anticipated later this year.
  • Revenues for the three months ended June 30, 2022 were $1.6 million, compared to $1.1 million for the three months ended March 31, 2022.

DGAP-News: va-Q-tec: Global specialist for TempChain transport solutions and energy efficiency continues on successful track in the first half of 2022

Retrieved on: 
Thursday, August 11, 2022
Product, Industry, CEO, Uponor, Technology, Growth, EUR, Investment, ISIN, Sale, Saskatchewan River Sturgeon Management Board, Construction, EBITDA, Depreciation, Solution, ...Continued, Airline, Renewable energy, System, Group, Service

Revenue growth in the first half of 2022 was very gratifying overall despite the challenging macroeconomic environment, thanks to the highly sought-after product and service portfolio.

Key Points: 
  • Revenue growth in the first half of 2022 was very gratifying overall despite the challenging macroeconomic environment, thanks to the highly sought-after product and service portfolio.
  • Revenues increased strongly by 17% year-on-year to EUR55.4million in the first half of 2022 (H1 2021: EUR47.3million).
  • The coronavirus business accounted for 13% of revenues in the first half of 2022, compared with also 13% in H1 2021.
  • Overall, the non-Covid-related TempChain business thereby grew by +28% in the first half of 2022 and the TempChain business as a whole grew by +25%.

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Epithelial cell adhesion molecule, GLOBE, AbbVie, Cancer, Investment, Clinical trial, Research, Patient, Bi-specific T-cell engager, Tumor microenvironment, Nivolumab, ...Continued, TCB, Risk, NIVO, Ipilimumab, SAN, Partnership, Safety, Webcast, Nasdaq, ID, Interferon, ESMO, ADC, IFN, Preclinical development, Therapeutic index, American Association for Cancer Research, Neoplasm, Therapy, COVID-19, Program, Amgen, AACR, Triple-negative breast cancer, Bristol Myers Squibb, United, Ministry of Education (Malaysia), CD71, CD166, IND, Twitter, EGFR, CD3, LinkedIn, Progression-free survival, Conjugation, Pharmaceutical industry, Video game, Vaccine, Fine chemical, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • A data update for the fully enrolled squamous non-small cell lung cancer cohort is expected in the fourth quarter of 2022.
  • CytomX has prioritized the development of CX-2051 and an IND submission is planned in the second half of 2023.
  • General and administrative expenses increased by $2.4 million during the second quarter of 2022 to $11.7 million.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.

Soluna Holdings Announces June Site Level Financials

Retrieved on: 
Wednesday, July 20, 2022
Environment, GLOBE, Intend, CEO, Kilowatt-hour, NASDAQ, Weather, ...Continued, Cycle, Miner, Contribution margin, BTC, TVA, Cryptocurrency, Coal

ALBANY, NY, July 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Soluna Holdings, Inc. (“SHI” or the “Company”), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. (“SCI”), a developer of green data centers for cryptocurrency mining and other intensive computing, today announced the release of its June site level financials.

Key Points: 
  • Despite Continued BTC Price Decreases in June, Soluna Continues to Grow Hashrate and Intends to Invest through the Cycle
    ALBANY, NY, July 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Soluna Holdings, Inc. (SHI or the Company), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. (SCI),a developer of green data centers for cryptocurrency mining and other intensive computing, today announced the release of its June site level financials.
  • Michael Toporek, CEO of Soluna Holdings, stated, Soluna continues to prove its business model despite a decline in BTC price.
  • The companys strong operating base of ultra-low energy cost assets have continued to perform well as they were designed to do in challenging macro environments.
  • Seasonal factors affect revenue in June, but increased capacity softens impact
    Average Hashrate deployed was flat Month-over-Month with peak hashrate remaining above 1 EH/s.